search
Back to results

A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ Prolapsed

Primary Purpose

Pelvic Organ Prolapse

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Seratom® PA mesh
Sponsored by
Samyang Biopharmaceuticals Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pelvic Organ Prolapse focused on measuring Partially absorbable mesh

Eligibility Criteria

41 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Woman who aged 41 years or older
  2. Subjects who have symptomatic pelvic organ prolapse quantification(POP-Q) stage II & cystocele or higher requiring surgical repair
  3. Subjects who desires vaginal reconstructive surgery
  4. Subjects who have uterus < 12 weeks size
  5. Subjects who are able to complete study questionnaires and assessment
  6. Subjects who are available for 6 months follow-up

Exclusion Criteria:

  1. Subjects who have medical contractions, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use, or a compromised immune system
  2. Subjects who have received anticoagulation therapy
  3. Subjects who are on current intermittent catheterization
  4. Subjects whose BMI is over 30kg/m2
  5. Subjects who have uncontrolled diabetes
  6. Subjects who are on any medication which could result in compromised immune response, such as immune modulators
  7. Subjects who are currently pregnant or intends to become pregnant during the study period or <12 months post-partum
  8. Subjects who have received other laparoscopic or abdominal or pelvic surgery in the past 1 months
  9. Subjects who need for concomitant surgery requiring an abdominal incision
  10. Subjects who have had a prior prolapse implant procedure (i.e. IVS tunneler, Perigee, Apogee, graft augmented repair, etc)

    • Note: previous traditional repairs are allowed.
  11. Subjects who have had radiation therapy to the pelvic area
  12. Subjects who have pelvic cancer or have had pelvic cancer within the past 12 months or have had on cytostatic medication within the past 12 months
  13. Subjects who have a shortened vagina or other known Mullerian anomaly (e.g. uterine didelphys.)
  14. Subjects who have a known neurologic or medical condition affecting bladder function (e.g. Multiple Sclerosis, spinal cord injury)
  15. Subjects who have a known hypersensitivity to the graft material(s)

Sites / Locations

  • Samyang Biopharmaceuticals

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Seratom® PA mesh

Arm Description

Partially absorbable mesh

Outcomes

Primary Outcome Measures

Pelvic Organ Prolapse Quantification(POP-Q) stage
Surgical revision rate

Secondary Outcome Measures

No of patients complications occurred

Full Information

First Posted
December 9, 2014
Last Updated
April 27, 2017
Sponsor
Samyang Biopharmaceuticals Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT02320643
Brief Title
A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ Prolapsed
Official Title
A Prospective Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh(Seratom PA®) in Patients With Pelvic Organ Prolapsed
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
December 2014 (Actual)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
April 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Samyang Biopharmaceuticals Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy, recurrence, postoperative complications of partially absorbable mesh(Seratom®PA) in patients with pelvic organ prolapse.
Detailed Description
Patients with pelvic organ prolapse are administrated partially absorbable mesh(Seratom®PA). It is performed pelvic organ prolapse quantification(POP-Q) examination, quality of life(QOL) questionnaire complications at postop 2week, 12week, 24week.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pelvic Organ Prolapse
Keywords
Partially absorbable mesh

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Seratom® PA mesh
Arm Type
Experimental
Arm Description
Partially absorbable mesh
Intervention Type
Device
Intervention Name(s)
Seratom® PA mesh
Intervention Description
Partially absorbable mesh
Primary Outcome Measure Information:
Title
Pelvic Organ Prolapse Quantification(POP-Q) stage
Time Frame
Change from baseline in Pelvic Organ Prolapse Quantification(POP-Q) stage at postop 2week, 12week, 24week
Title
Surgical revision rate
Time Frame
For post op 6 months from baseline
Secondary Outcome Measure Information:
Title
No of patients complications occurred
Time Frame
For post op 6 months from baseline

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
41 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Woman who aged 41 years or older Subjects who have symptomatic pelvic organ prolapse quantification(POP-Q) stage II & cystocele or higher requiring surgical repair Subjects who desires vaginal reconstructive surgery Subjects who have uterus < 12 weeks size Subjects who are able to complete study questionnaires and assessment Subjects who are available for 6 months follow-up Exclusion Criteria: Subjects who have medical contractions, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use, or a compromised immune system Subjects who have received anticoagulation therapy Subjects who are on current intermittent catheterization Subjects whose BMI is over 30kg/m2 Subjects who have uncontrolled diabetes Subjects who are on any medication which could result in compromised immune response, such as immune modulators Subjects who are currently pregnant or intends to become pregnant during the study period or <12 months post-partum Subjects who have received other laparoscopic or abdominal or pelvic surgery in the past 1 months Subjects who need for concomitant surgery requiring an abdominal incision Subjects who have had a prior prolapse implant procedure (i.e. IVS tunneler, Perigee, Apogee, graft augmented repair, etc) Note: previous traditional repairs are allowed. Subjects who have had radiation therapy to the pelvic area Subjects who have pelvic cancer or have had pelvic cancer within the past 12 months or have had on cytostatic medication within the past 12 months Subjects who have a shortened vagina or other known Mullerian anomaly (e.g. uterine didelphys.) Subjects who have a known neurologic or medical condition affecting bladder function (e.g. Multiple Sclerosis, spinal cord injury) Subjects who have a known hypersensitivity to the graft material(s)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kwon Sang Hoon, Doctor
Organizational Affiliation
Keimyung University Dongsan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samyang Biopharmaceuticals
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ Prolapsed

We'll reach out to this number within 24 hrs